CAMBRIDGE, Mass., Oct. 15, 2020 /PRNewswire/ -- Leap
Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused
on developing targeted and immuno-oncology therapeutics, today
announced the Company will be presenting esophagogastric cancer
data for its DKN-01 monoclonal antibody at the Society of
Immunotherapy of Cancer's (SITC) 35th Anniversary Annual
Meeting, being held November 9-14,
2020 virtually.
Leap Presentation Details:
Title: Tumoral DKK1
expression correlates with better clinical outcomes in patients
with advanced esophagogastric cancer (EGC) treated with DKN-01
Presenter: Samuel J.
Klempner, MD, Massachusetts General Hospital Cancer
Center
Abstract ID: 262
Date: Available on demand on Monday,
November 9, 2020 at 8:00 a.m.
ET
About DKN-01
DKN-01 is a humanized monoclonal antibody
that binds to and blocks the activity of the Dickkopf-1
(DKK1) protein, a modulator of
Wnt/Beta-catenin signaling, a signaling pathway frequently
implicated in tumorigenesis and suppressing the immune system.
DKK1 has an important role in tumor
cell signaling and in mediating an immuno-suppressive tumor
microenvironment through enhancing the activity of myeloid-derived
suppressor cells and downregulating NK ligands on tumor cells. The
U.S. Food and Drug Administration has granted DKN-01 Orphan Drug
Designation for the treatment of gastric and gastroesophageal
junction cancer and Fast Track Designation in combination with
tislelizumab for the treatment of patients with gastric and
gastroesophageal junction adenocarcinoma whose tumors express high
DKK1 protein, following disease
progression on or after prior fluoropyrimidine- and platinum-
containing chemotherapy and if appropriate, human epidermal
receptor growth factor (HER2)/neu-targeted therapy.
About Leap Therapeutics
Leap
Therapeutics (Nasdaq:LPTX) is focused on developing targeted
and immuno-oncology therapeutics. Leap's most advanced clinical
candidate, DKN-01, is a humanized monoclonal antibody targeting the
Dickkopf-1 (DKK1) protein, a Wnt
pathway modulator. DKN-01 is in clinical trials in patients with
esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
Leap has entered into a collaboration with BeiGene, Ltd. for the
rights to develop DKN-01 in Asia
(excluding Japan), Australia, and New
Zealand. For more information about Leap Therapeutics, visit
http://www.leaptx.com or view our public filings with the SEC that
are available via EDGAR at http://www.sec.gov or via
https://investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include Leap's expectations with
respect to the development and advancement of DKN-01, including the
initiation, timing and design of future studies, enrollment in
future studies, potential for the receipt of future option
exercise, milestones or royalty payments from BeiGene, and other
future expectations, plans and prospects. Although Leap believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, forward-looking statements are
subject to known and unknown risks, uncertainties and other factors
that could cause actual results to differ materially from our
expectations. Such risks and uncertainties include, but are not
limited to: that the initiation, conduct, and completion of
clinical trials, laboratory operations, manufacturing campaigns,
and other studies may be delayed, adversely affected, or impacted
by COVID-19 related issues; the accuracy of our estimates regarding
expenses, future revenues, capital requirements and needs for
financing; the outcome, cost, and timing of our product development
activities and clinical trials; the uncertain clinical development
process, including the risk that clinical trials may not have an
effective design or generate positive results; our ability to
obtain and maintain regulatory approval of our drug product
candidates; the size and growth potential of the markets for our
drug product candidates; our ability to continue obtaining and
maintaining intellectual property protection for our drug product
candidates; and other risks. Detailed information regarding factors
that may cause actual results to differ materially will be included
in Leap Therapeutics' periodic filings with the SEC, including
Leap's Annual Report on Form 10-K for the fiscal year ended
December 31, 2019, as filed with the
SEC on March 16, 2020 and as may be
updated by Leap's Quarterly Reports on Form 10-Q and the other
reports Leap files from time to time with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Leap undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Heather Savelle
Investor Relations
Argot Partners
212-600-1902
heather@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-present-esophagogastric-cancer-data-at-sitc-2020-annual-meeting-301152831.html
SOURCE Leap Therapeutics, Inc.